Viewing Study NCT00383240



Ignite Creation Date: 2024-05-05 @ 5:04 PM
Last Modification Date: 2024-10-26 @ 9:27 AM
Study NCT ID: NCT00383240
Status: COMPLETED
Last Update Posted: 2024-05-20
First Post: 2006-09-29

Brief Title: Effects of Mometasone FuroateFormoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics Study P04334AM1COMPLETED
Sponsor: Organon and Co
Organization: Organon and Co

Study Overview

Official Title: A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone FuroateFormoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids
Status: COMPLETED
Status Verified Date: 2022-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a randomized multi-center double-blind double-dummy placebo-controlled parallel-group study evaluating the efficacy of mometasone furoate MF formoterol fumarate FMFF metered dose inhaler MDI versus MF for 26 weeks Prior to the 26-week double-blind Treatment Period subjects will receive open-label MF MDI 200 mcg twice daily BID for 2 to 3 weeks during the Run-in Period Efficacy will be measured by The Area Under the Curve From 0 to 12 Hours AUC0-12 hours of the Change From Baseline to the Week 12 Endpoint

in Forced Expiratory Volume in One Second FEV1 Time Frame Baseline to Week 12 and Time-to-First Severe Asthma Exacerbation across the 26-week treatment period
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
EUDRACT No 2006-001578-25 None None None